¹Ù·Î°¡±â ¸Þ´º
º»¹®³»¿ë ¹Ù·Î°¡±â

2016³â ½ÉÇ÷°ü Ãá°èÅëÇÕÇмú´ëȸ Á¦8ȸ ¾Æ½Ã¾Æ · ÅÂÆò¾ç ½ÉºÎÀü Çмú´ëȸ

ÇÐȸº° ÀÏÁ¤

´ëÇѽÉÀåÇÐȸ ´ëÇѺÎÁ¤¸ÆÇÐȸ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Çѱ¹½ÉÃÊÀ½ÆÄÇÐȸ Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ ¼øÈ¯±âÀǰøÇÐȸ

´ëÇѽÉÀåÇÐȸ

Vascular April 20, 09:30-11:00 Rm.101
Inflammation & Atherosclerosis
Chairpersons ÇÏÁ¾¿ø, Á¤Çؾï
Panel °­½ÃÇõ, ±èÀÀÁÖ, ¹ÚÀçÇü
09:30-09:45 Clinical Evidence of Association between Inflammation and CVD À̼±±â/ÇѸ²ÀÇ´ë
09:45-10:00 Conventional Anti-Inflammatory Therapy for Atherosclerosis ¹ÚÁø¼±/¾ÆÁÖÀÇ´ë
10:00-10:15 Target for Anti-Inflammatory Therapy in Immune Cell & Cytokine Á¤Çý¹®/°æÈñÀÇ´ë
10:15-10:30 Anti-Inflammatory Therapy with Canakinumab for Atherosclerosis(CANTOS Trial) ÀÌÂùÁÖ/¿¬¼¼ÀÇ´ë
10:30-10:45 Previous Trials of Anti-Inflammatory Therapy, before CANTOS Trial ÀÌÇØ¿µ/¼­¿ïÀÇ´ë
10:45-11:00 Discussion
Myocardial Infarction 1 April 20, 09:30-11:00 Rm.201
Beyond Evidence-Based 'To Do and Not to Do'
Chairpersons 伺ö, Á¤¸íÈ£
Panel ±èµ¿±â, ¹ÚÁ¾¼±, ¹èÀåȯ, ÀÌÀåÈÆ, Àå±âÀ°
09:30-09:50 Time Target in STEMI: D2B Time or FMC to Wire Crossing? À±Ã¢È¯/¼­¿ïÀÇ´ë
09:50-10:10 Optimizing DAPT Duration after AMI: Evidence-Based, Precision, or Personalized
Medicine?
¹Ú¿ëÈÖ/°æ»óÀÇ´ë
10:10-10:30 Complete Immediate Revascularization in Primary PCI Is The New Standard of Care? ÀÌÁÖ¸í/¼º±Õ°üÀÇ´ë
10:30-10:50 Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA);
Medical Therapy and Outcome
À±ÇõÁØ/°è¸íÀÇ´ë
10:50-11:00 Discussion
Women Heart Disease April 20, 11:10-12:40 Rm.101
Aging & Heart in Women
Chairpersons ½É¿ÏÁÖ, À±È£Áß
Panel ±èÇзÉ, ½Å¹Ì½Â, ¿À¼¼ÀÏ, À¯Ã¶¿õ
11:10-11:30 Frailty & Sarcopenia in Women ±è±¤ÀÏ/¼­¿ïÀÇ´ë
11:30-11:50 Obesity and Visceral Fat in Women ¹Ú¼º¹Ì/°í·ÁÀÇ´ë
11:50-12:10 Atrial Fibrillation - What Are Worse in Women À¯ÈñÅÂ/¿¬¼¼ÀÇ´ë
12:10-12:30 Degenerative Aortic Stenosis & TAVI in Elder Women ¹Ú´ö¿ì/¿ï»êÀÇ´ë
12:30-12:40 Discussion
Hypertension April 20, 11:10-12:40 Rm.103
Unresolved Issues in HT
Chairpersons ±èöȣ, Á¶¸íÂù
11:10-11:35 How Should We Measure Blood Pressure in the Post SPRINT, Post Mercury
Sphygmomanometer Era
½ÅÁøÈ£/ÇѾçÀÇ´ë
11:35-12:00 Efficacy of Blood Pressure Control in Stage 1, Low Risk Hypertension ¹Ú¼ºÇÏ/¿¬¼¼ÀÇ´ë
12:00-12:25 Updates on Device Therapy for Resistant Hypertension Àå±âÀ°/°¡Å縯ÀÇ´ë
12:25-12:40 Discussion
Myocardial Infarction 2 April 20, 11:10-12:40 Rm.201
Emerging Lanscape
Chairpersons ±èÁ¾Áø, ±èÈ¿¼ö
Panel ±èÇö±¹, ÀÌ»ó¿±, Á¶Áø¸¸, Çã½ÂÈ£, ȲÁø¿ë
11:10-11:30 Rehabilitation Following Myocardial Infarction ÀÌÁ¾¿µ/¼º±Õ°üÀÇ´ë
11:30-11:50 Sudden Cardiac Death Early after AMI: Risk Stratification Methods and Primary
Prevention
ÇѼº¿í/°è¸íÀÇ´ë
11:50-12:10 Needle to Scalpel for Myocardial Infarction: Surgeon's Point of View ±èÁعü/¿ï»êÀÇ´ë
12:10-12:30 Mood and Mind after Myocardial Infarction ±èÀç¹Î/Àü³²ÀÇ´ë
12:30-12:40 Discussion
Scientific Session [MSD] April 20, 12:40-13:20 Rm.101
The Latest Updates on the Management of Patients with CVD
Chairpersons Á¤¿í¼º, ±ÇÇöö
12:40-13:00 Indispensable Role of Ezetimibe/Atorvastatin Combination Therapy in ACS/CHD Patients ÇѱâÈÆ/¿ï»êÀÇ´ë
13:00-13:20 Re-evaluate Diabetes Treatment Focusing on the CV Risk Patients ±èÇý¼ø/°è¸íÀÇ´ë
Scientific Session [Boryung] April 20, 12:40-13:20 Rm.103
Hypertension : Update 2018
Chairpersons ½Â±â¹è, ÇÏÁ¾¿ø
12:40-13:00 Evaluation the Antihypertensive Efficacy of Fimasartan vs. Valsartan Monotherapy Á¤¿ì¹é/°¡Å縯ÀÇ´ë
13:00-13:20 The Next Treatment Strategy for Hypertension Patient ±èº´±Ø/¿¬¼¼ÀÇ´ë
Scientific Session [Hanmi] April 20, 12:40-13:20 Rm.105
Optimal CVD Control with Triple Therapy Based on "Amlodipine/Losartan" FDC
Chairpersons Â÷ÅÂÁØ, È«¹ü±â
12:40-13:00 Evidence-based Approach for Intensive BP Control ±èÀÀÁÖ/°í·ÁÀÇ´ë
13:00-13:20 Towards Optimal Management of CV Risk in Hypertensive Patients with Dyslipidemia ¹Ú¿ìÁ¤/ÇѸ²ÀÇ´ë
Scientific Session [Pfizer] April 20, 12:40-13:20 Rm.107
Secondary CV Prevention: Where We Are Now?
Chairpersons ʽÂÁ¦, ±èÈ¿¼ö
12:40-13:00 The Latest Updates on the Management of Patients with CHD ³²Ã¢¿í/°è¸íÀÇ´ë
13:00-13:20 Personalized Lipid-Lowering Therapy in High Risk Patients ÀÌ»óÇÐ/¿¬¼¼ÀÇ´ë
Scientific Session [Bayer] April 20, 12:40-13:20 Rm.201
Confidence through Real World Experience with Rivaroxaban
Chairpersons ±è¿µÈÆ, ÀüÀº¼®
12:40-13:00 The First Prospective, Observational Study with Rivaroxaban in NVAF Patients in Asia:
XANAP
½ÉÀç¹Î/°í·ÁÀÇ´ë
13:00-13:20 Renal Outcomes in Anticoagulation Treatment with Rivaroxaban À̱âÈ«/Àü³²ÀÇ´ë
Scientific Session [BMS] April 20, 12:40-13:20 Rm.202
Choose the Right NOAC to Protect AF Patients from Stroke and Bleedings
Chairpersons ¼ºÀÎȯ, ½Åµ¿±¸
12:40-13:00 Patient in Focus: What Is the Role of Apixaban in Managing Elderly/CKD Patient
with AF
¹ÚÇü¿í/Àü³²ÀÇ´ë
13:00-13:20 Patient in Focus: What Is the Role of Apixaban in Managing AF Patient with Coronary
Artery Disease
È«¼øÁØ/°í·ÁÀÇ´ë
[English Session] Memorial Lecture April 20, 13:40-14:30 Rm.202
Chairperson Seung-Jung Park
13:40-13:55 In Memory of Suh, Soon Kyu Wan Joo Shim/Korea Univ., Korea
13:55-14:25 Cardiac Repair after Myocardial Infarction Steven Houser/Temple Univ., USA
Heart Failure 1 April 20, 14:30-16:00 Rm.103
Management of Advanced Heart Failure
Chairpersons À¯±ÔÇü, °­¼®¹Î
Panel ±è¸í¾Æ, ½Å¹Ì½Â, Á¶ÇöÀç, ÃÖÁø¿À
14:30-14:45 Cardiorenal Syndrome ¿ÀÀç¿ø/¿¬¼¼ÀÇ´ë
14:45-15:00 Diuretic Resistance: How to Manage? ÀÌÁÖÈñ/ÃæºÏÀÇ´ë
15:00-15:15 Hyponatremia in HF ¹ÚÁøÁÖ/¼­¿ïÀÇ´ë
15:15-15:30 RV Failure in the Patients with Left-Sided HF À±Á¾Âù/ÇѸ²ÀÇ´ë
15:30-16:00 Discussion
[English Session] Cardiometabolic Syndrome April 20, 16:10-17:40 Rm.103
Crosstalk in Cardiometabolic Syndrome
Chairpersons Hong Seog Seo, Kwang Kon Koh
Panel Sang-Hyun Kim, Ki Chul Sung, Il Suk Sohn, Sang-Ho Jo
16:10-16:30 IRAK-1 Phosphorylates IRS-1 on Ser24: Crosstalk Relevant to the Pathophysiology of
Cardiometabolic Syndrome
Michael J. Quon/University of Maryland, USA
16:30-16:40 Discussion
16:40-16:55 Gut Microbiota and Metabolic Disorders Seong-Eun Kim/Ewha Womans Univ., Korea
16:55-17:10 Dynamic Crosstalk between Immune System and Cardiometabolic Diseases Jong-Chan Youn/Hallym Univ., Korea
17:10-17:25 Cardiometabolic Crosstalk in Obesity-Related Hypertension Sungha Park/Yonsei Univ., Korea
17:25-17:40 Discussion
Smart Healthcare April 20, 16:10-17:40 Rm.202
Application of Smart Healthcare in Cardiovascular Disease
Chairpersons ¹Ú½Â¿ì, ±è¿ëÁø
16:10-16:35 Development of Medical Big Data Platform ¹Ú°æ¹Î/¿ï»êÀÇ´ë
16:35-17:00 Retinal Damage as the Window to Cardiovascular Organ Damage: Use of Machine
Learning of Retinal Damage to Predict the Presence of Cardiovascular Target Organ
Damage
ÀÓÇüÅÃ/¿¬¼¼ÀÇ´ë
17:00-17:25 Remote Monitoring of Heart Failure Patients ¹ÚÁøÁÖ/¼­¿ïÀÇ´ë
17:25-17:40 Discussion
Imaging April 21, 09:00-10:30 Rm.101
Multimodality Imaging in Valvular Heart Disease and Valvular Calcification
Chairpersons ¼ÛÀç°ü, °­¿øÁØ
09:00-09:20 Role of Imagings in VHD Management ÀÌ»óö/¼º±Õ°üÀÇ´ë
09:20-09:40 Initial Assessment of VHD with Echocardiography À±¿¬ÀÌ/¼­¿ïÀÇ´ë
09:40-10:00 The Role of CT/MRI in VHD ¾çµ¿Çö/¿ï»êÀÇ´ë
10:00-10:20 The Assessment of Valvular Inflammation/Calcification Using PET ÆØÁøÃ¶/¼­¿ïÀÇ´ë
[English Session] Epidemiology April 21, 09:00-10:30 Rm.103
Epidemiologic Research Using National Big Data
Chairpersons Sang Hong Baek, Boyoung Joung
Panel Jang-Whan Bae, Ki Chul Sung, Song Vogue Ahn, Jin Yong Hwang
09:00-09:20 CVD Epidemiologic Studies Using The UK Health Improvement Network (THIN) Database G. Neil Thomas/
The University of Birmingham, UK
09:20-09:35 CVD Burden in Cancer Patients: National Health Insurance Service-National Sample
Cohort (NHIS-NSC)
Jong-Chan Youn/Hallym Univ., Korea
09:35-09:50 Long-Term Risk Factor Changes and CVD: National Health Insurance Service-Health
Screening Cohort (NHIS-HEALS)
Hyeon Chang Kim/Yonsei Univ., Korea
09:50-10:05 CVD Event Ascertainment with Health Insurance Claims and Hospital Records Min Ho Shin/
Chonnam National Univ., Korea
10:05-10:30 Discussion
Adult Congenital Heart Disease April 21, 09:00-10:30 Rm.107
Chairpersons °íÀç°ï, ¹Ú½Â¿ì
Panel ±èÁö³ª, ¼Û¹Ì°æ, Á¶È­Áø
09:00-09:15 Risk Factors for Cerebrovascular Problem in ACHD Á¤Áø¸¸/°í·ÁÀÇ´ë
09:15-09:30 Cardiac Rehabilitation with Daily Activity and Exercise in ACHD ÇãÁØ/¼º±Õ°üÀÇ´ë
09:30-09:45 Hematologic Issues of Eisenmenger Syndrome in ACHD ±è¼ºÈ£/¼¼Á¾º´¿ø
09:45-10:00 Congestive Hepatopathy in ACHD ¹éÀç¼÷/¿ï»êÀÇ´ë
10:00-10:15 How to Prevent and Manage Infectious Endocarditis in ACHD ±è¼ºÇý/ÇѸ²ÀÇ´ë
10:15-10:30 Discussion
Health Policy April 21, 10:40-12:10 Rm.101
Regional Variability in Cardio-Vascular Health Care Delivery
Chairpersons ¿Àµ¿Áø, ¹ÚÇö¿µ
Panel ±èº´¿Á, ±èÇý·¡, ¹®°Ç¿õ, Á¤¿ì¿µ
10:40-11:00 Regional Disparity in Survival Outcomes of Acute Myocardial Infarction ¹èÀåȯ/ÃæºÏÀÇ´ë
11:00-11:20 Regional Variation in Emergency Service Use in Cardio-Vascular Diseases ±èÀ±/¼­¿ïÀÇ´ë
11:20-11:40 ½É³úÇ÷°üÁúȯ°ü¸® Á¾ÇÕ°èȹ-Implementation of a Regional Heathcare Network ±è³²¼ø/º¸°Ç»çȸ¿¬±¸¿ø
11:40-12:00 Role of Primary Stroke Center in Improving Accessiblity in the Rural Setting Àå¹Î¿í/ÇѸ²ÀÇ´ë
Cardiac Surgery April 21, 10:40-12:10 Rm.103
Current State-of-the-Art of Coronary Artery Surgery
Chairpersons À¯°æÁ¾, À±Á¤¼·
10:40-10:55 SYNTAX, EXCEL, NOBLE and Current Comparative Studies about PCI vs. CABG À̱âÁ¾/¿¬¼¼ÀÇ´ë
10:55-11:10 Total Arterial Grafting (TAR): Should We Apply TAR to All Patients? Á¶±¤¸®/¼¼Á¾º´¿ø
11:10-11:25 On-Pump vs. Off-Pump CABG: Which Is Better Now? À±¿µ³²/¿¬¼¼ÀÇ´ë
11:25-11:40 Can Composite Grafting Supply The Entire Heart? Ȳȣ¿µ/¼­¿ïÀÇ´ë
11:40-11:50 How to Improve Surgical Results : Prevention of Stroke after CABG °­ÁرÔ/°¡Å縯ÀÇ´ë
11:50-12:00 How to Improve Surgical Results : Prevention of Atrial Fibrillation after CABG À̽ÂÇö/¿¬¼¼ÀÇ´ë
12:00-12:10 Discussion
Pediatric Cardiology April 21, 10:40-12:10 Rm.107
Coronary Artery Problems
Chairpersons ±è¿µÈÖ, ÃÖÀ翵
Panel Àº¿µ¹Î, ÀÌ»óÀ±, Çϱâ¼ö
10:40-10:55 Congenital Abnormality of Coronary Artery with Long-Term Outcomes
(Origin, ALCAPA, Fistula)
ÀÌÇüµÎ/ºÎ»êÀÇ´ë
10:55-11:10 Combined Coronary Problem with Congenital Heart Disease - TOF DORV TGV µî ÀÌÀ翵/°¡Å縯ÀÇ´ë
11:10-11:25 Acquired Coronary Problem in Children and Adolescent ±è±â¹ü/¼­¿ïÀÇ´ë
11:25-11:40 Imaging of Coronary Problem in Children Á¤Á¶¿ø/¿¬¼¼ÀÇ´ë
11:40-11:55 Intervention of Coronary Problem in Children Àå¼ÒÀÍ/¼¼Á¾º´¿ø
11:55-12:10 Discussion
[Joint Session] Imaging & Intervention April 21, 10:40-12:10 Rm.201
Treatment of Coronary Artery Disease: 40 Years of PCI, Where Next?
Chairpersons ¼ÛÀç°ü, ÇѱԷÏ
Panel ±è¿µÇÐ, ±èÁß¼±, ±èÇü°ü, ³²Ã¢¿í, ½Å¼ºÈñ, ÀÌ»óö, Á¤Çؾï, Á¶º´·Ä
40 Years of PCI: We Should Know Each Other!!!
10:40-10:55 PCI as Contributor to CV Outcome Improvements ¾È¿µ±Ù/Àü³²ÀÇ´ë
10:55-11:10 CV Imaging as Contributor to CV Outcome Improvements È«±×·ç/¿¬¼¼ÀÇ´ë
11:10-11:25 Discussion
40 Years of PCI: Invasive vs. Non-Invasive Contibution in the Management of Coronary Disease in the Contemporary Era
11:25-11:40 Interventionist View: PCI Guided by FFR and IVUS ±¸º»±Ç/¼­¿ïÀÇ´ë
11:40-11:55 Imaging Specialist View: Viablity Assessment with CV Imaging; Echo, Nuclear Imaging,
CMR, and More
±èÇü¼·/°è¸íÀÇ´ë
11:55-12:10 Discussion
Scientific Session [Daiichisankyo-Daewoong] April 21, 12:10-12:50 Rm.103
Achieving Best Outcomes for Patients with Cardiovascular Disease with Olmesartan and Edoxaban
Chairpersons ÃÖ±âÁØ, °­¼®¹Î
12:10-12:30 Improving Management of Hypertension ¼ÕÀϼ®/°æÈñÀÇ´ë
12:30-12:50 Engaging with the Real-World: NOACs in Korea Focusing on Edoxaban ÃÖÀDZÙ/¼­¿ïÀÇ´ë
Scientific Session [Takeda] April 21, 12:10-12:50 Rm.105
New ARB, Edarbi for New Hypertensive Patients
Chairpersons Á¶¸íÂù, ±èµ¿¼ö
12:10-12:40 New ARB, Edarbi for New Hypertensive Patients ±è¿ëÁø/¼­¿ïÀÇ´ë
Scientific Session [Samjin] April 21, 12:10-12:50 Rm.107
Risk Management of Cardiovascular and Cerebrovascular Disease and Treatment of NOAC
Chairpersons Àüµ¿¿î, äÀÎÈ£
12:10-12:30 °íÇ÷¾ÐȯÀÚ¿¡¼­ ½ÉÇ÷°üÁúȯÀÇ À§Çèµµ °ü¸® ÀÌÁØÈñ/ÇѸ²ÀÇ´ë
12:30-12:50 Real-World Evidence of NOACs on Stroke Prevention on AF Patients: Where Are We
Now?
À̼ҷÉ/¼øÃµÇâÀÇ´ë
Diamond Session [Bayer] April 21, 12:10-12:50 Rm.201
Protecting Multi-Morbid Patients with NVAF through Responsible Use of Rivaroxaban
Chairpersons ÇѱԷÏ, ±è´ë°æ
12:10-12:30 What¡¯s Your Choice of NOAC for Patients with NAVF Undergoing PCI? ÇÑÁÖ¿ë/¼º±Õ°üÀÇ´ë
12:30-12:50 How Do You Appropriately Treat Multi-Morbid Patients with NVAF? ¹ÚÇü¼·/°è¸íÀÇ´ë
Diamond Session [BMS] April 21, 12:10-12:50 Rm.202
How Inconsistent Is NOAC Dosing in AF?
Chairpersons ±è³²È£, ¿Â¿µ±Ù
12:10-12:30 Appropriateness of NOAC Dosing to Prevent Stroke and Bleedings in AF ±èÅÂÈÆ/¿¬¼¼ÀÇ´ë
12:30-12:50 Choosing the Right NOAC at the Right Dose for the Right Patients ±èÀ¯¸®/°¡Å縯ÀÇ´ë
Heart Failure 2 April 21, 13:10-14:30 Rm.103
Updates in Management of HF
Chairpersons 伺ö, ÃÖµ¿ÁÖ
Panel ¹Ú´ë±Õ, ½Å¹Ì½Â, È«¼®±Ù
13:10-13:25 Recent Updates in HF Care ±èÀÀÁÖ/°í·ÁÀÇ´ë
13:25-13:40 ICD for Primary Prevention of Nonischemic Cardiomyopathy ÀÌ»ó¾ð/¿ï»êÀÇ´ë
13:40-13:55 Management of HF with Recovered EF Á¶À翵/Àü³²ÀÇ´ë
13:55-14:10 How to Improve Quality of Care of HF À¯º´¼ö/¿¬¼¼ÀÇ´ë
14:10-14:30 Discussion
[English Session] Basic Research 1 April 21, 13:10-14:30 Rm.105
Inflammatory Signaling in Heart and Vascular Disease
Chairpersons Donghoon Choi, Youngkeun Ahn
Panel Young Mi Park, Jaewon Oh, Sang-Hak Lee, Seung Hwan Han
13:10-13:25 SREBP1 and Inflammatory Signaling Yumiko Oishi/Nippon Medical School
13:25-13:40 The Roles of Myeloid Cells in Atherosclerosis Jae Hoon Choi/Hanyang Univ., Korea
13:40-13:55 A Heart-brain-kidney Network Controls Adaptation to Cardiac Stress through Tissue
Macrophage Activation
Katsuhito Fujiu/Tokyo Univ., Japan
13:55-14:10 Role of HDAC in Vascular Calcification and Cardiovascular Disease Gwang Hyeon Eom/
Chonnam National Univ., Korea
14:10-14:30 Discussion
[English Session] Pediatric Cardiac Surgery 1 April 21, 13:10-14:30 Rm.107
Coronary Artery Anomalies
Chairpersons Young Hwan Park, Myung Chul Hyun
Panel Jae Gun Kwak, Chun Soo Park, Hong Ju Shin
13:10-13:20 Surgical Options for Congenital Coronary Anomalies Han Ki Park/Yonsei Univ., Korea
13:20-13:30 Difficult Coronaries in Arterial Switch Operation Woong-Han Kim/
Seoul National Univ., Korea
13:30-13:40 Pediatric CABG Ji-Hyuk Yang/
Sungkyunkwan Uiniv., Korea
13:40-13:55 Current Status of Pediatric VAD Support Iki Adachi/Texas Children¡¯s Hospital, USA
13:55-14:10 The World Database for Pediatric and Congenital Heart Surgery:
A Tool for Global Quality Improvement
James D. St. Louis/
Children¡¯s Mercy Hospital, USA
14:10-14:30 Discussion
Heart Failure 3 April 21, 14:40-16:00 Rm.103
Discuss with Cases
Chairpersons ÀÌ»óÈÆ, ±èÀçÁß
Panel ¹ÚÀçÇü, Á¤Áø¿Á, Á¶»óÈ£, ÇѼº¿ì
14:40-14:55 Cardiac Sarcoidosis ±èÀº°æ/¼º±Õ°üÀÇ´ë
14:55-15:10 Pulmonary Hypertension and RV Dysfunction ÃÖÁ¤Çö/ºÎ»êÀÇ´ë
15:10-15:25 Myocarditis ±èÀÎö/°è¸íÀÇ´ë
15:25-15:40 Hypertropic Cardiomyopathy: Variable Manifestations Àå¼¼¿ë/°æºÏÀÇ´ë
15:40-16:00 Discussion
[English Session] Basic Research 2 April 21, 14:40-16:00 Rm.105
Cardiac Metabolism
Chairpersons Myeong-Chan Cho, Sang Hong Baek
Panel Yong Sook Kim, Hyoung Kyu Kim, Pil-Ki Min, Hyun-Young Park, Sang-Hyun Ihm
14:40-14:55 Ca2+ Regulation in Heart Failure Steven R. Houser/Temple Univ., USA
14:55-15:10 Akt1 and Akt2 Are Required to Maintain Cardiac Contraction Jaetaek Kim/Chung-Ang Univ., Korea
15:10-15:25 TRPC Channels in Cardiac Plasticity Motohiro Nishida/
National Institutes of Natural Sciences, Japan
15:25-15:40 Angiotensin II Affects Inflammation Mechanisms via AMPK-Related Signalling Pathways
in HL-1 Atrial Myocytes
Hyeon Soo Kim/Korea Univ., Korea
15:40-16:00 Discussion
[English Session] Pediatric Cardiac Surgery 2 April 21, 14:40-16:00 Rm.107
Atrioventricular Valves
Chairpersons Si Chan Sung, Tae Gook Jun
Panel Hyungtae Kim, Yu Rim Shin, Cheul Lee
14:40-14:52 Surgical Options for Ebstein¡¯s Anomaly Tae-Jin Yun/Ulsan Univ., Korea
14:52-15:04 Management of TR in Patients with Repaired TOF Chang-Ha Lee/
Sejong General Hospital, Korea
15:04-15:16 Surgical Options for Congenital Mitral Valve Diseases Cheul Lee/Catholic Univ., Korea
15:16-15:31 Repair of Complete Atrioventricular Canal Defects: Surgical Techniques and Outcomes James D. St. Louis/
Children¡¯s Mercy Hospital, USA
15:31-15:46 Cardiac Recovery on VAD Iki Adachi/Texas Children¡¯s Hospital, USA
15:46-16:00 Discussion

´ëÇѺÎÁ¤¸ÆÇÐȸ

KHRS 1 Apr.20(Fri) 09:30-11:00 Rm.202
ECG Interpretation: A Case-Based Review
Chairpersons À̸í¿ë, À强¿ø
Case °íÁ¡¼®, ±èÁÖ¿¬, ¹é¿ë¼ö, ½Åµ¿±Ý, ¾ÈÁøÈñ, À̼ҷÉ, ÀÌÇý¿µ, Á¶¿µÁø
KHRS 2 Apr.20(Fri) 11:10-12:40 Rm.202
Stroke Summit: Stroke Prevention and Anticoagulation
Chairpersons À̸¸¿µ, ÃÖ±âÁØ, ±è´ë°æ
Panel ±èµ¿Çõ, ¹è¸íȯ, ¾È¹Î¼ö, À̱¤³ë, ÃÖ¿µ
11:10-11:20 Risk Stratification of Stroke and Thromboembolism in Atrial Fibrillation ±èÅÂÈÆ/¿¬¼¼ÀÇ´ë
11:20-11:30 Anticoagulation Guideline for Korean ÀÌÁ¤¸í/°æÈñÀÇ´ë
11:30-11:40 Characteristics of NOAC °íÁ¡¼®/¿ø±¤ÀÇ´ë
11:40-11:50 Selection Anticoagulation for High Bleeding Risk Patients À̱âÈ«/Àü³²ÀÇ´ë
11:50-12:00 LAA Occluder ÀÓÈ«ÀÇ/°í·ÁÀÇ´ë
12:00-12:15 Asian Strategy for Stroke Prevention in Atrial Fibrillation Tze-Fan Chao/
Taipei Veterans General Hospital, Taiwan
12:15-12:40 Discussion
KHRS 3 Apr.20(Fri) 14:30-16:00 Rm.202
AF Summit: Atrial Fibrillation
Chairpersons ±è¿µÈÆ, Â÷ÅÂÁØ, ±è´ëÇõ
Panel ±èÁÖ¿¬, ±èÁØÇü, ±èÁø¹è, ±èÁø¼®, ¹Úȯö
14:30-14:40 Integrated Management of Atrial Fibrillation ¹ÚÁعü/ÀÌÈ­ÀÇ´ë
14:40-14:50 Rate Control of Atrial Fibrillation ÃÖÀDZÙ/¼­¿ïÀÇ´ë
14:50-15:00 Rhythm Control of Atrial Fibrillation ½ÉÀç¹Î/°í·ÁÀÇ´ë
15:00-15:10 Outcomes of AF Ablation ¹ÚÈñ³²/¿¬¼¼ÀÇ´ë
15:10-15:20 New Techniques for Atrial Fibrillation Ablation ÇѼº¿í/°è¸íÀÇ´ë
15:20-15:40 Scar and Atrial Fibrillation Nassir Marrouche/University of Utah, USA
15:40-16:00 Discussion
KHRS 4 (ºÎÁ¤¸Æ-½ÉºÎÀü Joint Session) Apr.21(Sat) 10:40-12:10 Rm.202
Device Therapy in Heart Failure
Chairpersons ½Åµ¿±¸, ÃÖµ¿ÁÖ
Panel °­¼®¹Î, ³ë½Â¿µ, ¾çÇʼº, È«¼®±Ù
10:40-10:50 ICD and CRT - Benefit and Guideline ÀÌ¿µ¼ö/´ë±¸°¡Å縯ÀÇ´ë
10:50-11:00 How to Select the Case for ICD and CRT? ¹ÚÀçÇü/Ãæ³²ÀÇ´ë
11:00-11:10 When Is Best Time to Refer Patient for CRT ±è°èÈÆ/Àü³²ÀÇ´ë
11:10-11:20 Monitoring of HF Patients with Devices À¯º´¼ö/¿¬¼¼ÀÇ´ë
11:20-11:30 How to Prevent Inappropriate Shock? ¹Ú½ÂÁ¤/¼º±Õ°üÀÇ´ë
11:30-11:40 ICD and CRT Are More Effective in Asian HF Patients? Á¤º¸¿µ/¿¬¼¼ÀÇ´ë
11:40-11:50 The Role of VT Ablation in the Latest Guideline ¹ÚÇü¼·/°è¸íÀÇ´ë
11:50-12:10 Discussion
KHRS 5 Apr.21(Sat) 13:10-14:30 Rm.202
PSVT and VT
Chairpersons ¿Àµ¿Áø, À̹®Çü, ¿À¿ë¼®
Panel ±ÇâÈñ, ¹ÚÁø±Ô, ¹ÚÇü¿í, ÀÌ´ëÀÎ, ÀåÁø±Ù
13:10-13:20 The Efficient and Smart Methods for Diagnosis of SVT ¿À¼¼ÀÏ/¼­¿ïÀÇ´ë
13:20-13:30 WPW, AVRT ±è¼ºÈ¯/°¡Å縯ÀÇ´ë
13:30-13:40 EKG Localization: Outflow VT ±èÁø¼®/°í·ÁÀÇ´ë
13:40-13:50 EKG Localization: Non-Outflow VT ±èÀ¯¸®/°¡Å縯ÀÇ´ë
13:50-14:00 Management of VT Without Structural Heart Disease ¹Ú°æ¹Î/¼º±Õ°üÀÇ´ë
14:00-14:10 Management of VT With Structural Heart Disease ³²±âº´/¿ï»êÀÇ´ë
14:10-14:30 Discussion
KHRS 6 Apr.21(Sat) 14:40-16:00 Rm.202
CIED and Sudden Cardiac Death
Chairpersons °ûÃæÈ¯, Á¤º´Ãµ, ±è³²È£
Panel °­±â¿î, ±èµ¿¹Î, ³²±ÃÁØ, À¯ÈñÅÂ, ÇÑ»óÁø
14:40-14:50 Should Device-Detected AF Be Treated? À±³²½Ä/Àü³²ÀÇ´ë
14:50-15:00 Solving Complication During CIED Followup ±èÁØ/¿ï»êÀÇ´ë
15:00-15:10 Management of CIED Infection and Lead Extraction ¹Ú»ó¿ø/¼¼Á¾º´¿ø
15:10-15:20 New Technique in CIED: Subcutaenous ICD, Leadless Pacemaker, Etc ¼ºÁ¤ÈÆ/Â÷ÀÇ´ë
15:20-15:30 Role of Genetic Testing in Arrhythmia ÃÖÁ¾ÀÏ/°í·ÁÀÇ´ë
15:30-15:40 Substrate and Risk Stratification in ARVD/C Á¶¿ë±Ù/°æºÏÀÇ´ë
15:40-16:00 Discussion

´ëÇѽÉÇ÷°üÁßÀçÇÐȸ

KSIC 1 April 20, 14:30-16:00 Rm. 201
How to PCI: Lectures for Beginning Cardiologists
Chairpersons ¹Ú½ÂÁ¤, ȲÈï°ï
Panel ¹ÚÇå½Ä, ¾È¼º±Õ, À±°æÈ£, À̼ºÀ±, ÃÖ¼Ò¿¬, Çã½ÂÈ£
14:30-14:45 History of Interventional Cardiology  ±ÇÇöö/¼º±Õ°üÀÇ´ë
14:45-15:00 Access Site Basics: Transfemoral and Transradial Accesses & Its Closure À̺À±â/°­¿øÀÇ´ë
15:00-15:15 What You See Is Not What You Get: Using Intravascular Imaging to Complement
Angiography 
È«¿µÁØ/Àü³²ÀÇ´ë
15:15-15:30 Into the Heart: Catheter and Wire Selection  ÀÌÀçȯ/Ãæ³²ÀÇ´ë
15:30-15:45 Don't Be Panic: How to Manage Acute Complications  Àü±¹Áø/ºÎ»êÀÇ´ë
15:45-16:00 Discussion
KSIC II April 20, 16:10-17:40 Rm. 201
Dr., I Have Chest Pain: Non-interventional Management
Chairpersons ½Â±â¹è, ¾ÈÅÂÈÆ
Panel ±èµÎÀÏ, µµÁØÇü, ÀÌöȯ, äÁ¦°Ç, ÃÖÁøÈ£, Æí¿í¹ü
16:10-16:25 Strategy of Non-invasive Testing  È«¼øÁØ/°í·ÁÀÇ´ë
16:25-16:40 Antiplatelet Therapy, Before and After PCI  ¹Ú¿ëÈÖ/°æ»óÀÇ´ë
16:40-16:55 Optimal Management for Dyslipidemia ±è¼öÁß/°æÈñÀÇ´ë
16:55-17:10 Antianginal Treatment, The Art of Medical Therapy  Á¤¿µÈÆ/°æ»óÀÇ´ë
17:10-17:25 NOAC after PCI in AF Patients ¹èÀåȯ/ÃæºÏÀÇ´ë
17:25-17:40 Discussion
KSIC III April 21, 09:00-10:30 Rm. 201
Take the Next Step in PCI: Treating Complex and Higher-Risk Indicated Patients (CHIP)
Chairpersons Seung Jea Tahk, Kyoo Rok Han
Panel Sang Wook Kim, Ung Kim, Hee Yeol Kim, Seok Kyu Oh, Jun-Hee Lee, Seung Hwan Han
09:00-09:15 Using Imaging and Physiology Guidance in Higher Risk Patients Jung-Min Ahn/Ulsan Univ., Korea
09:15-09:30 PCI in Calcified Lesions  Byeong-Keuk Kim/Yonsei Univ., Korea
09:30-09:45 PCI in Bifurcation Sunao Nakamura/
New Tokyo Hospital, Japan
09:45-10:00 PCI during AMI: Complete vs. Culprit-only Revascularization  Joo-Yong Hahn/Sungkyunkwan Univ., Korea
10:00-10:15 PCI in SVG Lesions  Seung-Woon Rha/Korea Univ., Korea
10:15-10:30 Discussion
KSIC IV April 21, 13:10-14:30 Rm. 201
TAVR and Beyond
Chairpersons Á¤¸íÈ£, ±èÈ¿¼ö
Panel °í¿µ±¹, ±èÁÖÇÑ, ¹ÚÁ¾¼±, äÀÎÈ£, ÃÖ½ÂÇõ
13:10-13:23 Future Indications of TAVR: Low Risk Patients, Younger Patients, Asymptomatic Patients À¯Ã¶¿õ/°í·ÁÀÇ´ë
13:23-13:36 Medical Treatment After TAVR  ¹Ú´ö¿ì/¿ï»êÀÇ´ë
13:36-13:49 Valve-in-valve TAVR: Technical Pearls and Outcomes ±èÈ¿¼ö/¼­¿ïÀÇ´ë
13:49-14:02 Durability of TAVR Valve : Bench Test & Clinical Evidence Compared with SAVR Àå±âÀ°/°¡Å縯ÀÇ´ë
14:02-14:15 Transcatheter Mitral and Tricuspid Valve Therapies  ±èÁØÈ«/ºÎ»êÀÇ´ë
14:15-14:30 Discussion
KSIC V April 21, 14:40-16:00 Rm. 201
Hemodynamic Support
Chairpersons À±Á¤ÇÑ, ±è¹«Çö
Panel °íÀ±¼®, ±è¿ø, ¼Û¿µºó, ¾çÅÂÇö, Á¤¿ì¿µ, ÃÖµ¿ÈÆ
14:40-14:53 IABP  °­½ÃÇõ/¼­¿ïÀÇ´ë
14:53-15:06 ECMO ¹ÚÅñÔ/¼º±Õ°üÀÇ´ë
15:06-15:19 VAD Á¤¼ºÈ£/¿ï»êÀÇ´ë
15:19-15:32 Hemodynamic Support in CHIP: Provisional vs Routine  °­¿õö/°¡ÃµÀÇ´ë
15:32-15:45 Future Devices for Mechanical Circulatory Support in Cardiogenic Shock and High-Risk
PCI
¼­¼®¹Î/°¡Å縯ÀÇ´ë
15:45-16:00 Discussion

Çѱ¹½ÉÃÊÀ½ÆÄÇÐȸ

KSE 1 April 20, 14:30-16:00 Rm. 101
Issues Regarding Valvular Diseases
Chairpersons ±è±â½Ä, À±È£Áß
14:30-14:50 Echo-Doppler Evaluation in Aortic Stenosis È«±×·ç/¿¬¼¼ÀÇ´ë
14:50-15:10 Echo-Doppler Evaluation in Aortic Regurgitation ÀÌ»óö/¼º±Õ°üÀÇ´ë
15:10-15:30 Echo-Doppler Evaluation in Mitral Regurgitation ±è¿ëÁø/¼­¿ïÀÇ´ë
15:30-15:50 Echo-Doppler Evaluation in Tricuspid Regurgitation ±è°èÈÆ/Àü³²ÀÇ´ë
15:50-16:00 Discussion
KSE 2 April 20, 16:10-17:40 Rm. 101
Instructive Cases Assessed by Echo and Its Friends
Chairpersons ¼ÛÀç°ü, ÀÓ¼¼Áß
Panel ¹ÚÀçÇü, ¹ÚÅÂÈ£, ¼ÛÁ¾¹Î, Á¤Çؾï, Á¶±¸¿µ
16:10-16:30 Aortic Stenosis: Moderate or Severe? ½Å¼ºÈñ/ÀÎÇÏÀÇ´ë
16:30-16:50 Aortic Regurgitation: When the Etiological Evaluation Is Critical ȲÈñÁ¤/°æÈñÀÇ´ë
16:50-17:10 Tricuspid Regurgitation: Surgery or Not? ±èÇзÉ/¼­¿ïÀÇ´ë
17:10-17:30 Prosthetic Valves: Normal or Abnormal? ¹Ú¼º¹Ì/°í·ÁÀÇ´ë
17:30-17:40 Discussion
KSE 3 April 21, 13:10-14:40 Rm. 101
Issues Regarding Hypertrophic Cardiomyopathy
Chairpersons ±èµ¿¼ö, ¹Ú½Â¿ì
13:10-13:30 Overview of Hypertrophic Cardiomyopathy ±èÇü°ü/¼­¿ïÀÇ´ë
13:30-13:50 Myocardial and Non-myocardial Alterations Found in Hypertrophic Cardiomyopathy:
Assessment with Echo and Its Friends
±è¹ÌÁ¤/°¡Å縯ÀÇ´ë
13:50-14:10 Differential Diagnosis of Hypertrophied Myocardium ¼ÕÀϼ®/°æÈñÀÇ´ë
14:10-14:30 Surgical Treatment in Hypertrophic Cardiomyopathy: How, When, and Whom? ±è¿í¼º/¼º±Õ°üÀÇ´ë
14:30-14:40 Discussion
KSE 4 April 21, 14:40-16:10 Rm. 101
Instructive Cases Assessed by Echo and Its Friends
Chairpersons ±ÇÁØ, ½ÅÁØÇÑ
Panel ¹Ú¿ëÇö, À¯½Â±â, À±ÇöÁÖ, Á¶ÀºÁÖ, ÃÖÀÇ¿µ
14:40-15:00 Hypertrophic Cardiomyopathy or Not? ¼ÕÁ¤¿ì/¿¬¼¼¿øÁÖÀÇ´ë
15:00-15:20 Restrictive Cardiomyopathy: Cardiac Amyloidosis and Its Mimics ¾çµ¿Çå/°æºÏÀÇ´ë
15:20-15:40 Constrictive Pericarditis: Medical vs. Surgical. What's Your Choice? À强¾Æ/¼º±Õ°üÀÇ´ë
15:40-16:00 Regional Wall Motion Abnormality: Ischemic vs. Non-ischemic. That's the Question! ±è°æÈñ/¼¼Á¾º´¿ø
16:00-16:10 Discussion

Çѱ¹ÁöÁú¡¤µ¿¸Æ°æÈ­ÇÐȸ

KSoLA 1 April 20, 09:30-11:00 Rm. 107
Vascular Inflammation and Remodeling
Chairpersons ±èÈ¿¼ö, ¿À±¸ÅÃ
Panel ¹Ú¿µ¹Ì, ¹ÚÁ¾±æ, Á¶°æÇö, Á¶ÇöÀç, ÇÑÁø
09:30-09:50 Role of Dendritic Cells in Vascular Inflammation   ÃÖÀçÈÆ/ÇѾç´ë
09:50-10:10 Vessel Remodeling in Pulmonary Hypertension   ±èÁ¾¹Î/¼÷¸í¿©´ë
10:10-10:30 Vessel Remodeling in Diabetic Retinopathy   À±Ã¢È¯/¼­¿ïÀÇ´ë
10:30-10:50 Regulation of Atherosclerosis by Calpain Proteolytic Systems  Takuro Miyazaki/Showa University, Japan
10:50-11:00 Discussion
KSoLA 2 April 20, 11:10-12:40 Rm. 107
Understanding Cardiometabolic Nutrition: A Cell to Neighborhood Perspective
Chairpersons ¼­È«¼®, À̸í¼÷
Panel °­ÇöÀç, ±è»óÇö, ±èÀçÅÃ, ½Å¹ÎÁ¤, ÀÌ»óÇÐ
11:10-11:30 Ectopic Olfactory Receptors Regulate Cellular Lipid Metabolism and Adiposity  À̼ºÁØ/°í·Á´ë
11:30-11:50 Nutritional Systems Biology Approach for Understanding Homeostatic Protection of
Botanical Phytochemicals Against Vascular Endothelial Dysfunction in Human Clinical
Trials 
±Ç¿À¶õ/ÀÌÈ­¿©´ë
11:50-12:10 Social Determinant and Cardiometabolic Risks: Diet as a Mediator  ±è¿À¿¬/µ¿¾Æ´ë
12:10-12:30 Impact of Social Network Characteristics on Cardiometabolic Health   ±èÇöâ/¿¬¼¼ÀÇ´ë
12:30-12:40 Discussion
KSoLA 3 April 20, 13:40-14:30 Rm. 107
Debate Session ; Highly Intensive Lipid Lowering Therapy in DM without CVD
- CV Risk and LDL-Cholesterol Target
Chairpersons À̹®±Ô, ¿ìÁ¤ÅÃ
Panel ±èÇö¹Î, ±èÇýÁø, ¹®¹Î°æ, ¹ÚÇü±Ô, È«¼øÁØ
13:40-13:50 Pros   ±èÀçÇö/¼º±Õ°üÀÇ´ë
13:50-14:00 Cons   ÀÌ¿ìÁ¦/¿ï»êÀÇ´ë
14:00-14:10 Rebuttals
14:10-14:30 Discussion
KSoLA 4 April 20, 14:30-16:00 Rm. 107
Always Curious Questions ; Dyslipidemia and Atherosclerosis
Chairpersons Á¤¸íÈ£, ½ÅÇöÈ£
Panel ±è¿ëÀç, ±èÇзÉ, ¼­¿ì±Ù, À¯ÅÂÇö, ÀÓ¿µÈ¿
14:30-14:45 New Promising Lipid-Modifying Drugs   ÀÌ¿ëÈ£/¿¬¼¼ÀÇ´ë
14:45-15:00 Lipid-Lowering Therapy in ESRD Patient   ÀåÅÂÀÍ/±¹¹Î°Ç°­º¸Çè°ø´Ü
15:00-15:15 Management of Insignificant Arterial Stenosis   ¹Ú±¤¿­/Áß¾ÓÀÇ´ë
15:15-15:30 Exercise for Cardiometabolic Health   ±è¿µÁÖ/¼º½Å¿©´ë
15:30-15:45 Sleep and Cardiovascular Disease  ¾ç±¤ÀÍ/¼øÃµÇâÀÇ´ë
15:45-16:00 Discussion
KSoLA 5 April 20, 16:10-17:40 Rm. 107
Update session ; How to Interpret Recent CV Outcome Trials and Future Perspective
Chairpersons ±èÄ¡Á¤, ¹ÚÁß¿­
Panel ±èÁÖÇÑ, ¹ÚÀçÇü, ¹èÁöö, À̿ռö, ÀÌÀçÇõ
16:10-16:25 PCSK9 Inhibitors  ÀÌÀº¿µ/°¡Å縯ÀÇ´ë
16:25-16:40 What Do We Get from Recent Statin and CETP Inhibitors Trials?  ±èº´Áø/¼º±Õ°üÀÇ´ë
16:40-16:55 How to Interpret Recent CV Outcome Trials and Future: SGLT2 Inhibitors/ DPP4
Inhibitors / GLP-1 Analogues  
Á¤Àΰæ/°æÈñÀÇ´ë
16:55-17:10 NOACs in atherosclerotic CV disease  ÃÖ¼ºÈÆ/ÇѸ²ÀÇ´ë
17:10-17:40 Discussion

Çѱ¹ÁöÁú¡¤µ¿¸Æ°æÈ­ÇÐȸ

BEC 1 April 21, 09:00-10:30 Rm.105
Meet the Experts of Biomedical Engineering Society for Circulation 1
Chairpersons ÀÌ»óÁØ, À̺´±Ç
Panel ¾È¿¹Âù, ¿°Àº¼·, À̰èÇÑ, ÀÌ»óÇü
09:00-09:17 Àü»êÀ¯Ã¼¸¦ Ȱ¿ëÇÑ ¿¬¼º°íüÀÇ ±â°èÀû ¹°¼º°ú Rheology ÀÌÁØ»ó/¿¬¼¼´ë
09:17-09:34 Prediction of Plaque Progression Using FSI Simulation ÀåÇõÀç/¿¬¼¼ÀÇ´ë
09:34-09:51 CT-Derived Hemodynamics: Past, Present and Future ±¸º»±Ç/¼­¿ïÀÇ´ë
09:51-10:08 In-vitro 4-D MRI¸¦ ÀÌ¿ëÇÑ °æµ¿¸ÆÇùÂøÁõ ¼ö¼ú ÀüÈÄ Ç÷·ùÀ¯µ¿ ºñ±³ ¼Û½Ã¸ó/ÇѾç´ë
10:08-10:30 Discussion
BEC 2 April 21, 10:40-12:10 Rm.105
Meet the Experts of Biomedical Engineering Society for Circulation 2
Chairpersons À̰èÇÑ, ±è»ó¿í
Panel ¼Û½Ã¸ó, À¯À翵, ÀÌ»ó¿í, ÀåÇõÀç
10:40-10:57 Current Unmet Needs for Cerebro-Vascular Diseases ÀÌ»óÇü/¼­¿ïÀÇ´ë
10:57-11:14 Cerebral Venous Hemodynamics and Cerebrospinal Fluid ½ÉÀºº¸/°­¿ø´ë
11:14-11:31 Hemorheologic Characteristics in Women According as Menstruation Cycle À̺´±Ç/¿¬¼¼ÀÇ´ë
11:31-11:48 Diagnoses of Aged RBCs and Malaria with Holographic Microscopy & AI ÀÌ»óÁØ/POSTECH
11:48-12:10 Discussion
* POSTECH : Pohang University of Science and Technology